Remgro Limited provided earnings guidance for the year ended 30 June 2016. The company announced that reported headline earnings per share (HEPS) for the year ended June 30, 2016 is expected to be between 1,119.6 cents and 1,181.8 cents compared to the HEPS of 1,555.0 cents reported for the year ended June 30, 2015. The decrease in HEPS is mainly due to once-off transaction costs incurred with the Mediclinic International Limited (Mediclinic) rights issue and Al Noor Hospitals Group plc (Al Noor) transaction amounting to ZAR 788 million, of which ZAR 402 million is Remgro's own costs and ZAR 386 million is Remgro's share of Mediclinic's transaction costs, as well as a fair value adjustment of ZAR 730 million, relating to the increase in value of the bondholders' exchange option of the bonds (accounted for as a derivative liability) that were issued during March 2016 to partially refinance the foreign bridge funding that was raised for the Al Noor transaction.